Ambulation · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in ambulation compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Survival (long term) Over two years · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in survival (long term) Over two years compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Pain reduction · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in pain reduction compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Urinary continence One week after treatment · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in urinary continence One week after treatment compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Local recurrence · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
Quality of life · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease severity as measured by patient‐reported symptom score (total nasal symptom score) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Significant adverse event: epistaxis · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids probably leads to higher significant adverse event: epistaxis compared with placebo (moderate certainty).
1 finding from 1 review
Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · adults and children > 12 with non‐allergic rhinitis
It is very uncertain whether intranasal corticosteroids changes objective measurement of airflow: peak flow rate (expiratory) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids showed no clear difference in other adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 1 month (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 3 to 4 months (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids showed no clear difference in death in hospital; children compared with no such treatment (moderate certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids probably leads to lower need for mechanical ventilation at 1 month compared with no such treatment (moderate certainty).
1 finding from 1 review
Mortality within the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in all‐cause mortality (during the index hospital admission, or within… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Cardiac complications (as defined by study authors, including cardiac compromise and fatal and non‐fatal myocardial infarction, defined as ECG changes, echocardiological changes, or disproportionate elevation of troponins, during the index hospita... · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to higher cardiac complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower pulmonary complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Infectious complications · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower infectious complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review